Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Ward M, Goldman MD (2022) Epidemiology and pathophysiology of multiple sclerosis. Contin: Lifelong Learn Neurol 28(4):988–1005
2. Oh J (2022) Diagnosis of multiple sclerosis. Contin: Lifelong Learn Neurol 28(4):1006–1024
3. Khan F, Amatya B, Galea M (2014) Management of fatigue in persons with multiple sclerosis. Front Neurol 5:177
4. Foschi M, Lugaresi A (2019) Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? Expert Opin Pharmacother 20(11):1309–1320
5. Bakirtzis C, Konstantinopoulou E, Langdon D, Grigoriadou E, Minti F, Nikolaidis I et al (2018) Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: the IGNITE study. J Neurol Sci 395:106–112